

2024-05-08

## **SHORT CV Anders Kjellberg, MD PhD DESA EDIC**

**ICU Consultant, Head of Hyperbaric unit, Perioperative Medicine and Intensive Care, Karolinska University Hospital, Stockholm**

### **Contact**

Address: ME Intensive Care and Cardiothoracic surgery, F3:76 Hyperbaric medicine, Karolinska University Hospital, 171 76 STOCKHOLM

Telephone: Work +468-123 752 12, Mobile +46 760-65 73 55

Email: [anders.kjellberg@ki.se](mailto:anders.kjellberg@ki.se)

Website: [Anders Kjellberg- Karolinska Institutet](#)

### **Medical examinations**

2024 Doctor of Philosophy (PhD), Karolinska Institutet  
2013 European Diploma of Intensive Care Medicine (EDIC)  
2009 Diplomate of European Society of Anaesthesiology (DESA)  
2009 Specialist, Anaesthesia and Intensive Care  
2001 Licence to practice  
1999 Doctor of Medicine (MD), Göteborg University

### **Positions**

2024- Affiliated to research, Dept Physiology and Pharmacology, Karolinska Institutet, Stockholm  
2019-2024 PhD Student, Dept Physiology and Pharmacology, Karolinska Institutet, Stockholm  
2017- Senior Consultant ICU/Head of Hyperbaric unit, Perioperative medicine and Intensive Care, Karolinska University Hospital, Stockholm  
2013-2016 Specialist ICU, ANOPIVA, Karolinska University Hospital, Stockholm  
2011-2013 Senior Registrar ICU, Flinders Medical Centre, Adelaide, Australia  
2009-2011 Specialist Anaesthesia/ICU, VO Anaesthesia and Intensive Care, South Hospital  
2005-2009 Resident, VO Anaesthesia and Intensive Care, South Hospital, Stockholm  
2002-2010 Diving physician, Swedish Armed Forces (part time)  
1991-1993 Communications officer, HM Submarine Näcken, Swedish Armed Forces

### **Special assignments**

2022- Vice Chair Scandinavian Hyperbaric Medical Society (SHMS)  
2018-2022 Chair Scandinavian Hyperbaric Medical Society (SHMS)  
2018- Chair Swedish Society of Hyperbaric Medicine (SFHM)

### **Research interests and scope:**

My main area of interest is to find a suitable biomarker for individual HBOT dose-response with the overall aim to individualise treatment for better efficacy and safety. I perform clinical trials with HBOT compliant with ICH-GCP which is the international standard for pharmaceutical drugs. All trials include exploratory sub studies on mechanisms and biomarkers. My dissertation in February 2024 was on clinical trials with HBOT for COVID-19 and Long COVID. In my preclinical research I currently explore adjuvant HBOT in ovarian tissue transplantation and IVF treatment and we will hopefully launch a clinical trial later this year. I am part of the steering committee for the planned international multicentre randomised trial on HBOT for NSTI led by Professor Hyldegaard in Copenhagen.

## Publications:

1. Toppen W, Cho NY, Sareh S, **Kjellberg A**, Medak A, Benharash P, Lindholm P. Contemporary national outcomes of hyperbaric oxygen therapy in necrotizing soft tissue infections. *PLoS One*. 2024 Mar 21;19(3):e0300738.
2. **Kjellberg A**, Lindholm ME, Zheng X, Liwenborg L, Rodriguez-Wallberg KA, Catrina S-B, Lindholm P. Comparing the Blood Response to Hyperbaric Oxygen with High-Intensity Interval Training-A Crossover Study in Healthy Volunteers. *Antioxidants* 2023; 12: 2043.
3. **Kjellberg A**, Douglas J, Hassler A, Al-Ezerjawi S, Bostrom E, Abdel-Halim L, Liwenborg L, Hetting E, Jonasdottir Njastad AD, Kowalski J, Catrina SB, Rodriguez-Wallberg KA, Lindholm P. COVID-19-Induced Acute Respiratory Distress Syndrome Treated with Hyperbaric Oxygen: Interim Safety Report from a Randomized Clinical Trial (COVID-19-HBO). *J Clin Med* 2023; 12.
4. **Kjellberg A**, Hassler A, Bostrom E, El Gharbi S, Al-Ezerjawi S, Kowalski J, Rodriguez Wallberg KA, Bruchfeld J, Stahlberg M, Nygren-Bonnier M, Runold M, Lindholm P. Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial. *BMC Infect Dis* 2023; 23: 33.
5. **Kjellberg A**, Abdel-Halim L, Hassler A, El Gharbi S, Al-Ezerjawi S, Bostrom E, Sundberg CJ, Pernow J, Medson K, Kowalski JH, Rodriguez-Wallberg KA, Zheng X, Catrina S, Runold M, Stahlberg M, Bruchfeld J, Nygren-Bonnier M, Lindholm P. Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. *BMJ Open* 2022; 12: e061870.
6. **Kjellberg A**, Douglas J, Pawlik MT, et al. Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19. *BMJ Open*. 2021;11(7):e046738.
7. **Kjellberg A**, Bjerin O, Franzen-Rohl E, Bartek J, Jr., Lindholm P. Lemierre's syndrome caused by *Fusobacterium necrophorum* complicated with multiple brain abscesses-A case report, literature review, and suggested management. *Clin Case Rep*. 2021;9(12):e05142.
8. **Kjellberg A**, DeMaio A, Lindholm P. Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19? *Med Hypotheses*. 2020 Nov;144:110224. doi: 10.1016/j.mehy.2020.110224. Epub 2020 Aug 30.
9. Oscarsson N, Muller B, Rosen A, Lodding P, Molne J, Giglio D, Hjelle KM, Vaagbo G, Hyldegaard O, Vangedal M, Salling L, **Kjellberg A**, Lind F, Ettala O, Arola O, Seeman-Lodding H. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. *The lancet oncology* 2019; 20: 1602-1614.
10. **Kjellberg A**, Nystrom H, Soderberg M, Dlugosz A, Jornvall H, Steinberg A. Massive air embolism as a complication of upper gastrointestinal endoscopy: A case report illustrating a stroke mimic, literature review, and suggested management. *Clin Case Rep* 2018; 6: 1862-1867.
11. Svensson C, Teneberg S, Nilsson CL, **Kjellberg A**, Schwarz FP, Sharon N, Kregel U. High-resolution crystal structures of Erythrina cristagalli lectin in complex with lactose and 2'-alpha-L-fucosyllactose and correlation with thermodynamic binding data. *J Mol Biol*. 2002 Aug 2;321(1):69-83.
12. Backstrom M, Shahabi V, Johansson S, Teneberg S, **Kjellberg A**, Miller-Podraza H, Holmgren J, Lebens M. Structural basis for differential receptor binding of cholera and Escherichia coli heat-labile toxins: influence of heterologous amino acid substitutions in the cholera B-subunit. *Mol Microbiol*. 1997 May;24(3):489-97.
13. Karlsson KA, Teneberg S, Angstrom J, **Kjellberg A**, Hirst TR, Berstrom J, Miller-Podraza H. Unexpected carbohydrate cross-binding by Escherichia coli heat-labile enterotoxin. Recognition of

human and rabbit target cell glycoconjugates in comparison with cholera toxin. *Bioorg Med Chem.* 1996 Nov;4(11):1919-28.

#### **International abstracts and Conference contributions:**

1. **Kjellberg A**, Rodriguez-Wallberg K and Lindholm P. Efficacy and Safety of Hyperbaric oxygen for ARDS in patients with COVID-19; rationale and protocol of the randomized controlled trial COVID-19-HBO. *UHMS Evidence Review for HBO2 Treatment of COVID-19 Webinar June 2020 (Oral presentation)*
2. **Kjellberg A**, Zheng XW, Catrina SB and Lindholm P. Novel biomarkers for dose/effect of Hyperbaric oxygen and High Intensity Interval Training. *UHMS Annual Scientific Meeting 2020 (Abstract/Poster)*
3. **Kjellberg A** and Lindholm P. Hyperbaric Oxygen and turn of course in treatment-refractory multiple brain abscesses caused by *Fusobacterium necroforum*. *UHMS Annual Scientific Meeting 2020 (Abstract/Poster)*
4. **Kjellberg A**, Diakaki C, Hao X, Anastacio A, Rodriguez-Wallberg K. Hyperbaric oxygen preconditioning of ovarian tissue before cryopreservation modulate genes involved in follicle activation and anti-apoptotic pathways. *ASRM 2020 Scientific Congress and Expo. (Abstract/Poster)*
5. **Kjellberg A**, Douglas J, Al-Ezerjawi S, Boström E, Abdel-Halim L, Zhao A, Hetting E, Kowalski J, Skold M, Catrina SB, Rodriguez-Wallberg KA, Lindholm P. P9 – Är hyperbar oxygenbehandling säkert och effektivt för patienter med svår COVID-19? Preliminära resultat från kliniska läkemedelsprövningen COVID-19-HBO. 2021. *State of the Art Covid-19 2021 SLS (Abstract/Poster)*
6. **Kjellberg A**, Douglas J, Hassler A, Al-Ezerjawi S, Boström E, Abdel-Halim L, Liwenborg L, Zhao A, Hetting E, Jonasdottir-Njåstad A-D, Kowalski J, Catrina S-B, Rodriguez-Wallberg K and Lindholm P. Hyperbaric oxygen treatment appears to be safe for patients with severe COVID-19 and moderate ARDS. Interim safety results from the clinical trial COVID-19-HBO. *UHMS Annual Scientific Meeting 2022 (Abstract/Oral presentation)*
7. El Gharbi S, **Kjellberg A**, Hassler A, Boström E, Al-Ezerjawi S, Kowalski J, Catrina S-B, Rodriguez-Wallberg K, Runold M, Ståhlberg M, Bruchfeldt J, Nygren-Bonnier M, and Lindholm P. Safety of Hyperbaric Oxygen Treatment for Post COVID-19 condition. Results from the interim safety analysis of the randomized placebo-controlled double-blind trial (HOT-LoCO). *46<sup>th</sup> Annual Scientific Meeting EUBS 2022 (Abstract/Oral presentation)*
8. **Kjellberg A**, Lussier A, Hassler A, Al-Ezerjawi S, Boström E, Zhao A, Catrina S-B, Rodriguez-Wallberg K and Lindholm P. Inflammatory response profiles in COVID-19 patients treated with Hyperbaric Oxygen therapy compared with Best Practice. *UHMS Annual Scientific Meeting 2023 (Abstract/Poster)*
9. **Kjellberg A**, Lindholm P. Chronic fatigue/pain syndrome after DCS- a Medical Zebra or a hidden disease? *47<sup>th</sup> Annual Scientific Meeting EUBS 2023 (Abstract/Oral presentation)*